Trial No.: AstraZeneca D419QC00001 Caspian
A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease
On Hold Pending Availablilty of Etopside
Trial No.: BMS CA209-384
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240mg Every 2 Weeks vs Nivolumab 480mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3mg/kg or 240 mg Every 2 Weeks
©2018 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.